A Multicenter Open-Label Phase 1b Clinical Study of CMP-001 in Combination with Pembrolizumab in Subjects with Advanced Melanoma
Brief description of study
The purpose of this Phase 1b study is to study the effects of an investigational drug, CMP-001 (a capsid protein designed to induce anti-tumor response in immune cell types) in combination with Pembrolizumab (an anti-PD-1 antibody) in subjects with advanced cutaneous melanoma. This study will be conducted in two phases: a dose escalation phase and a dose expansion phase. Also immunogenicity and anticancer activity of CMP-001 in combination with Pembrolizumab will be assessed.
Clinical Study Identifier: s17-00314
ClinicalTrials.gov Identifier: NCTs17-00314
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
